🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification

Recruitingn/aAges 18 Years - anyAllRuijin Hospital
NCT07888374 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Urothelial carcinoma is the most common cancer of the urinary system. It includes bladder cancer and upper urinary tract cancer, which starts in the kidney pelvis or ureter. Doctors currently tell these types apart mainly by using invasive tests such as cystoscopy or ureteroscopy. These tests can be uncomfortable and may miss some tumors. This study is testing whether a urine sample can offer a simpler, non-invasive way to detect urothelial cancer and identify where the cancer started. This is a prospective, multicenter, observational study. It plans to enroll 477 adults, including 159 patients with upper urinary tract urothelial cancer, 159 patients with bladder cancer, and 159 people without cancer. Participants will provide a midstream urine sample of about 30 mL using a special collection tube. No experimental drug or device will be given. Participants will receive their usual medic

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Age ≥18 years at the time of enrollment. Participants must have hematuria and be undergoing evaluation for urothelial carcinoma. Cases: Histopathologically confirmed primary urothelial carcinoma of the bladder, renal pelvis, or ureter, with no prior anti-tumor treatment, including transurethral surgery, radical surgery, systemic or local chemotherapy, radiotherapy, or immunotherapy. Controls: No tumor or suspected space-occupying lesion confirmed by systematic examination, including urinary ultrasound or computed tomography. Complete clinical and pathological data available, including tumor location, stage, and grade for cases. Willingness to provide urine samples. Written informed consent obtained. Exclusion Criteria: History of malignant tumors at other sites. Blood transfusion within 7 days before urine sampling. History of organ transplantation or allogeneic hematopoietic stem cell transplantation. Any severe systemic disease, acute infection, or other condition that, in the investigator's judgment, may affect sample quality or study participation.
💊

What it tests

  • Not listed
📍

Where

1 site
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy